Alembic Secures USFDA Nod for Fingolimod Capsules in US Market

Alembic Pharmaceuticals has received final approval from the US Food and Drug Administration (USFDA) to market Fingolimod Capsules 0.5 mg in the United States. The approval marks another important step in the company’s efforts to strengthen its presence in the global generic medicines market.

The newly approved drug is a generic version of Gilenya, a widely prescribed treatment for multiple sclerosis treatment. Fingolimod is used to help reduce the frequency of relapses and slow the progression of physical disability in patients living with the disease. It is approved for use in adults as well as children aged 10 years and older.

Multiple sclerosis is a chronic condition that affects the central nervous system, disrupting communication between the brain and the body. Treatments such as Fingolimod help manage symptoms and improve quality of life by controlling immune system activity linked to the disease.

The approval was granted through the Abbreviated New Drug Application (ANDA) pathway, which allows pharmaceutical companies to launch lower-cost generic drug approval alternatives to branded medicines once patent protections expire. For Alembic, this approval opens up a new opportunity in the competitive US pharmaceutical market.

Also Read: Sun Pharma Organon Acquisition Boosts Global Pharma Rank

According to industry estimates, the Fingolimod Capsules market in the United States recorded annual sales of around $145 million in the 12 months ending December 2025. This creates a strong commercial opportunity as demand for affordable medicines continues to rise.

With this latest approval, Alembic continues expanding its portfolio in regulated pharmaceutical markets. The company has steadily increased its focus on drug manufacturing, research, and development to meet global healthcare demand.

Industry experts believe such approvals can strengthen Alembic’s position in the pharmaceutical industry while supporting long-term growth. As competition rises, regulatory approvals remain essential for companies looking to expand internationally and deliver cost-effective treatment options.